Spectral Diagnostics (OTCMKTS:EDTXF) Releases Quarterly Earnings Results, Meets Expectations

Spectral Diagnostics (OTCMKTS:EDTXF) announced its quarterly earnings data on Friday. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01), Zacks reports. The company had revenue of $0.64 million during the quarter, compared to analyst estimates of $0.54 million.

Spectral Diagnostics Trading Up 0.8%

Shares of OTCMKTS EDTXF opened at $1.03 on Friday. The stock has a market cap of $301.64 million, a P/E ratio of -10.28 and a beta of 0.09. Spectral Diagnostics has a 12-month low of $0.58 and a 12-month high of $1.31. The business’s fifty day simple moving average is $0.99 and its 200-day simple moving average is $0.99.

Spectral Diagnostics Company Profile

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.